Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma.

Applied immunohistochemistry & molecular morphology : AIMM - 1 Jan 2020

Zaidi Ariba, Gupta Parikshaa, Gupta Nalini, Rajwanshi Arvind, Rai Bhavana, Gainder Shalini

Abstract excerpt

AIM: The categorization of endometrial carcinomas into endometrioid and serous categories has prognostic implications but many-a-times, it is difficult to categorize based solely on morphology. The present study was conducted to determine an appropriate immunohistochemical panel to distinguish grade 3 endometrioid carcinoma from serous carcinoma. EXPERIMENTAL DESIGN: This study was a retrospective and a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Endometrioid
Share to Endometrial Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunohistochemistry

Share to Mutation

Share to Neoplasm Grading

Share to Neoplasm Proteins

Source

Identifiers

PMID: 31815745
DOI: 10.1097/PAI.0000000000000720

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma.PMID 31815745Read ↗

A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas.Semantic proximity Read ↗

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.Semantic proximity Read ↗

Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.Semantic proximity Read ↗

Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.Semantic proximity Read ↗

Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.Semantic proximity Read ↗

Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.Semantic proximity Read ↗

Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.Semantic proximity Read ↗

Endometrial endometrioid adenocarcinoma with a malignant squamous component: is the unusual metastatic pattern unique of these tumors?Semantic proximity Read ↗

The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.Semantic proximity Read ↗

When Is “Type I” Ovarian Cancer Not “Type I”? Indications of an Out-Dated DichotomySemantic proximity Read ↗

The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and ReproducibilitySemantic proximity Read ↗

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.